Alder Biopharmaceuticals to Participate in Antibody Therapeutics Panel at the RBC Capital Markets Global Healthcare Conference
Company to Include Lessons Learned from Developing Pipeline of Antibody Therapeutics Around New Technologies Including Clinical Development of ALD518
Feb 24, 2012, 08:00 ET
BOTHELL, Wash., Feb. 24, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that Randall Schatzman, Ph.D., president and chief executive officer, will participate in a panel focused on antibody therapeutics during the RBC Capital Markets Global Healthcare Conference in New York City at 10 a.m. EST on Tuesday, February 28.
"As a class antibody therapeutics have been highly successful, however there have been limitations to conventional technologies that have held the class back from reaching its full potential," said Schatzman. "We look forward to participating in this panel and discussing these limitations as well as potential solutions that are being applied by Alder to expand this class of therapeutics into non-traditional antibody markets, such as chronic migraine and cardiovascular disease."
About Alder Biopharmaceuticals
Alder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. ALD518 is an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6 that is being developed by Bristol-Myers Squibb for autoimmune indications. For more information, visit www.alderbio.com.
Media Contact:
Ian Stone or David Schull
Russo Partners
Tel: +1 619-528-2220
[email protected]
[email protected]
SOURCE Alder Biopharmaceuticals Inc.